Recruitment of FBXO22 for targeted degradation of NSD2.

Autor: Nie DY; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Tabor JR; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Li J; University of Florida Health Cancer Center, Gainesville, FL, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Kutera M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., St-Germain J; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Hanley RP; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; C4 Therapeutics, Watertown, MA, USA., Wolf E; Department of Chemistry, York University, Toronto, Ontario, Canada., Paulakonis E; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA., Kenney TMG; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Duan S; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Shrestha S; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Owens DDG; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Amphista Therapeutics, Cambridge, UK., Maitland MER; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Pon A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Szewczyk M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Lamberto AJ; University of Florida Health Cancer Center, Gainesville, FL, USA., Menes M; University of Florida Health Cancer Center, Gainesville, FL, USA., Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Penn LZ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Barsyte-Lovejoy D; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Brown NG; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Barsotti AM; Deerfield Discovery and Development, Deerfield Management, New York, NY, USA., Stamford AW; Deerfield Discovery and Development, Deerfield Management, New York, NY, USA., Collins JL; Office of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Wilson DJ; Department of Chemistry, York University, Toronto, Ontario, Canada., Raught B; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., James LI; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu., Arrowsmith CH; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2024 Dec; Vol. 20 (12), pp. 1597-1607. Date of Electronic Publication: 2024 Jul 04.